Compare MNTK & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNTK | EYPT |
|---|---|---|
| Founded | 1980 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.9M | 1.5B |
| IPO Year | 2021 | 2005 |
| Metric | MNTK | EYPT |
|---|---|---|
| Price | $1.83 | $18.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.33 | ★ $29.60 |
| AVG Volume (30 Days) | 129.5K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,682,000.00 | $42,339,000.00 |
| Revenue This Year | $2.45 | N/A |
| Revenue Next Year | $15.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $3.91 |
| 52 Week High | $4.96 | $19.11 |
| Indicator | MNTK | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 66.55 |
| Support Level | $1.77 | $16.52 |
| Resistance Level | $1.91 | $19.00 |
| Average True Range (ATR) | 0.11 | 1.04 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 55.87 | 74.24 |
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.